Skip to main content
Top
Published in: Sleep and Breathing 1/2020

01-03-2020 | Sleep Apnea | Sleep Breathing Physiology and Disorders • Original Article

Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study

Authors: Thomas Gaisl, Albina Nowak, Noriane A. Sievi, Nicolas Gerard, Christian F. Clarenbach, Malcolm Kohler, Daniel Franzen

Published in: Sleep and Breathing | Issue 1/2020

Login to get access

Abstract

Study objectives

Patients with Fabry disease (FD) report impaired quality of life and excessive daytime sleepiness. Obstructive sleep apnea (OSA) is frequently reported among patients with FD; however, its prevalence and its influence on quality of life and daytime sleepiness in this population are unclear.

Methods

Patients with FD in a cohort from the University Hospital Zurich (n = 52) were one-to-two matched to healthy adult controls (n = 104) according to age, sex, and body mass index. Participants underwent structured interviews (including Short Form-36) and level-3 respiratory polygraphy. An apnea-hypopnea index of ≥ 5/h was defined as OSA and the severity of FD was quantified with the Mainz Severity Score Index (MSSI). Conditional logistic regression was used to compare the outcomes.

Results

In patients with FD the mean MSSI was 13.3 ± 10.5 points and OSA prevalence was 19.2% vs. 9.0% in the matched control group (p = 0.09). The apnea-hypopnea index was significantly higher in patients with FD than in the control group (0.5/h [0.2–3.0] vs. 0.2/h [0.1–1.8], p = 0.026). OSA severity was associated with impaired quality of life in four dimensions for the whole study population. Furthermore, patients with FD did report significantly higher daytime sleepiness (Epworth Sleepiness Scale 7.6 points vs. 6.3 points; p = 0.01) than healthy controls.

Conclusion

Patients with mild FD do not have a higher OSA prevalence than matched control subjects. Differences in OSA severity did not reach clinical significance. Further studies are warranted to determine the impact of OSA in patients with moderate-to-severe FD.
Literature
1.
go back to reference Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40CrossRef Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40CrossRef
2.
go back to reference Desnick R, Ioannou Y, Eng C. (2001) α-galactosidase A Deficiency: Fabry disease. The metabolic and molecular bases of inherited disease. (eds Scriver CR, Beaudet AL, Sly WS, Valle D.) p3733-3774. In: McGraw-Hill, New York Desnick R, Ioannou Y, Eng C. (2001) α-galactosidase A Deficiency: Fabry disease. The metabolic and molecular bases of inherited disease. (eds Scriver CR, Beaudet AL, Sly WS, Valle D.) p3733-3774. In: McGraw-Hill, New York
3.
go back to reference Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338–346CrossRef Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338–346CrossRef
4.
go back to reference Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf el Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R (2016) Treatment of Fabry’s disease with the pharmacologic chaperone Migalastat. N Engl J Med 375(6):545–555CrossRef Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf el Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R (2016) Treatment of Fabry’s disease with the pharmacologic chaperone Migalastat. N Engl J Med 375(6):545–555CrossRef
5.
go back to reference Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M (2017) Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis 41(1):141–149CrossRef Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M (2017) Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis 41(1):141–149CrossRef
6.
go back to reference Duning T, Deppe M, Keller S, Schiffbauer H, Stypmann J, Böntert M, Schaefer R, Young P (2009) Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol 1(1):33–40CrossRef Duning T, Deppe M, Keller S, Schiffbauer H, Stypmann J, Böntert M, Schaefer R, Young P (2009) Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol 1(1):33–40CrossRef
7.
go back to reference Talbot A, Hammerschlag G, Goldin J, Nicholls K (2017) Sleep disturbance, obstructive sleep apnoea and abnormal periodic leg movements: very common problems in Fabry disease. JIMD Rep 31:37–44CrossRef Talbot A, Hammerschlag G, Goldin J, Nicholls K (2017) Sleep disturbance, obstructive sleep apnoea and abnormal periodic leg movements: very common problems in Fabry disease. JIMD Rep 31:37–44CrossRef
8.
go back to reference Franzen D, Gerard N, Bratton DJ, Wons A, Gaisl T, Sievi NA, Clarenbach CF, Kohler M, Krayenbühl PA (2015) Prevalence and risk factors of sleep disordered breathing in Fabry disease: a prospective cohort study. Medicine (Baltimore) 94(52):e2413CrossRef Franzen D, Gerard N, Bratton DJ, Wons A, Gaisl T, Sievi NA, Clarenbach CF, Kohler M, Krayenbühl PA (2015) Prevalence and risk factors of sleep disordered breathing in Fabry disease: a prospective cohort study. Medicine (Baltimore) 94(52):e2413CrossRef
9.
go back to reference Bratton DJ, Gaisl T, Schlatzer C, Kohler M (2015) Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med 3(11):869–878CrossRef Bratton DJ, Gaisl T, Schlatzer C, Kohler M (2015) Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med 3(11):869–878CrossRef
10.
go back to reference Kuhn E, Schwarz EI, Bratton DJ, Rossi VA, Kohler M (2017) Effects of CPAP and mandibular advancement devices on health-related quality of life in OSA: a systematic review and meta-analysis. Chest. 151(4):786–794CrossRef Kuhn E, Schwarz EI, Bratton DJ, Rossi VA, Kohler M (2017) Effects of CPAP and mandibular advancement devices on health-related quality of life in OSA: a systematic review and meta-analysis. Chest. 151(4):786–794CrossRef
11.
go back to reference Lacasse Y, Godbout C, Series F (2002) Health-related quality of life in obstructive sleep apnoea. Eur Respir J 19(3):499–503CrossRef Lacasse Y, Godbout C, Series F (2002) Health-related quality of life in obstructive sleep apnoea. Eur Respir J 19(3):499–503CrossRef
12.
go back to reference Lohle M, Hughes D, Milligan A, Richfield L, Reichmann H, Mehta A, Schapira AHV (2015) Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 84(14):1454–1464CrossRef Lohle M, Hughes D, Milligan A, Richfield L, Reichmann H, Mehta A, Schapira AHV (2015) Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 84(14):1454–1464CrossRef
13.
go back to reference Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J (2015) Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3(4):310–318CrossRef Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J (2015) Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3(4):310–318CrossRef
14.
go back to reference Bloch KE, Schoch OD, Zhang JN, Russi EW (1999) German version of the Epworth Sleepiness Scale. Respiration; international review of thoracic diseases 66(5):440–447CrossRef Bloch KE, Schoch OD, Zhang JN, Russi EW (1999) German version of the Epworth Sleepiness Scale. Respiration; international review of thoracic diseases 66(5):440–447CrossRef
15.
go back to reference Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef
16.
go back to reference Iber C American Academy of Sleep Medicine, Chesson AL, Qaun SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications (1st edn). Westchester: American Academy of Sleep Med Iber C American Academy of Sleep Medicine, Chesson AL, Qaun SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications (1st edn). Westchester: American Academy of Sleep Med
17.
go back to reference Cho JH, Kim HJ (2017) Validation of ApneaLink Plus for the diagnosis of sleep apnea. Sleep & breathing = Schlaf & Atmung 21(3):799–807CrossRef Cho JH, Kim HJ (2017) Validation of ApneaLink Plus for the diagnosis of sleep apnea. Sleep & breathing = Schlaf & Atmung 21(3):799–807CrossRef
18.
go back to reference Gaisl T, Giunta C, Bratton DJ, Sutherland K, Schlatzer C, Sievi N, Franzen D, Cistulli PA, Rohrbach M, Kohler M (2017) Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study. Thorax. 72(8):729–735CrossRef Gaisl T, Giunta C, Bratton DJ, Sutherland K, Schlatzer C, Sievi N, Franzen D, Cistulli PA, Rohrbach M, Kohler M (2017) Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study. Thorax. 72(8):729–735CrossRef
19.
go back to reference Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM (2013) Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177(9):1006–1014CrossRef Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM (2013) Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177(9):1006–1014CrossRef
20.
go back to reference Suhani P, Samantha SK, Claire MN et al (2017) Minimum clinically important difference of the Epworth Sleepiness Scale. Eur Respir J 50(Issue suppl):61 Suhani P, Samantha SK, Claire MN et al (2017) Minimum clinically important difference of the Epworth Sleepiness Scale. Eur Respir J 50(Issue suppl):61
21.
go back to reference El Shayeb M, Topfer LA, Stafinski T, Pawluk L, Menon D (2014) Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis. CMAJ. 186(1):E25–E51CrossRef El Shayeb M, Topfer LA, Stafinski T, Pawluk L, Menon D (2014) Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis. CMAJ. 186(1):E25–E51CrossRef
22.
go back to reference Corral J, Sanchez-Quiroga MA, Carmona-Bernal C et al (2017) Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Noninferiority, randomized controlled trial. Am J Respir Crit Care Med 196(9):1181–1190CrossRef Corral J, Sanchez-Quiroga MA, Carmona-Bernal C et al (2017) Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Noninferiority, randomized controlled trial. Am J Respir Crit Care Med 196(9):1181–1190CrossRef
Metadata
Title
Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study
Authors
Thomas Gaisl
Albina Nowak
Noriane A. Sievi
Nicolas Gerard
Christian F. Clarenbach
Malcolm Kohler
Daniel Franzen
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
Sleep and Breathing / Issue 1/2020
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-019-01832-4

Other articles of this Issue 1/2020

Sleep and Breathing 1/2020 Go to the issue

Epidemiology • Original Article

Sleep and hypertension